Novo Nordisk executive Camilla Sylvest says Australia generally has a relatively high prevalence of obesity compared with many other countries. Asked about the potential size of the Australian ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...

Australians pay some of the lowest medicine prices in the world for a reason: our Pharmaceutical Benefits Scheme. Here’s how ...

Globally, the rate of death from chronic kidney disease increased 24% from 1990 to 2021, according to statistics published by ...

HIGHLIGHTS •Aircore drilling to test priority targets expected to commence in late-March, weather dependent, at the Balla ...

Brazil's National Health Surveillance Agency (Anvisa) has approved the drug Awiqli, produced by the pharmaceutical company ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce alternative therapies ...

Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and ...

US medical giants say Australia’s Pharmaceutical Benefits Scheme is an “egregious and discriminatory” program that Trump ...

To further support cardiovascular health, Latrobe Health Services has funded the Healthy Hearts workplace program, which ...

There were tears of joy in Rome last month as negotiators reconvened to pick up where COP16 biodiversity talks left off last ...

Dwindling supplies of Ozempic are fuelling an “exploding” black market for the drug across Australia, as the medical industry is forced to assess which patients need the popular medication the most.